New insights into pathogenesis and potential therapeutic options for Graves orbitopathy

Current Opinion in Ophthalmology

Volumn 10, Issue 5, 1999, Pages 358-361

  Warwar, Ronald E ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE ANTIBODY; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; THYROTROPIN; THYROTROPIN RECEPTOR;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INFLAMMATION; ORBIT DISEASE; PRIORITY JOURNAL; REVIEW; THYROID DISEASE;

GRAVES DISEASE; HUMANS;

EID: 0032725639     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-199910000-00014     Document Type: Review

References (22)

1. Bahn R: A possible role for the thyrotropin receptor in thyroid-associated ophthalmopathy. Orbit 1996, 15:119-128.
2. Bahn R, Dutton C, Natt N, et al.: Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J din Endocrinol Metab 1998, 83:998-1002.
3. Bahn R, Dutton C, Joba W, Heufelder A: Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid 1998, 8:193-196.
4. Valyasevi R, Erickson D, Harteneck D, et al.: Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab, In press.
5. Wortsman J, Dietrich J, Traycoff R, Stone S: Preradial myxedema in thyroid disease. Arch Dermatol 1981, 117:635-638.
6. Bartalena L, Marcocci C, Bogazzi F, et al.: Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998, 338:73-78
7. Bahn R: The fibroblast is the target cell in the connective tissus manifestations of Graves' disease. Int Arch Allergy Immunol 1995, 106:213-218.
8. Wu Y, Clarke S, Shepherd P: Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid disease. Thyroid 1998, 8:167-174.
9. Major B, Busuttil B, Frauman A: Graves' ophthalmopathy: pathogenesis and clinical implications, Aust N 2 J Med 1998, 28:39-45.
10. Natt N, Bahn R: Cytokines in the evolution of Graves' ophthalmopathy. Autoimmunity 1997, 26:129-136.
11. Bahn R: Cytokines in thyroid eye disease: potential for anticytokine therapy. Thyroid 1998, 8:415-418. This paper reviews the role of cytokines in the pathogenesis of GO and the potential uses of anticytokine therapy.
12. Bahn R, Heufelder A: Mechanisms of disease: pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993, 329:1468-1475.
13. Heufelder A, Wenzel B, Bahn R: Cell surface localization of a 72 kilodalton heat shock protein in retroocular fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1992, 74:732-736.
14. DeBellis A, DiMartino S, Fiordelisi F, et al.: Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy. J Clin Endocrinol Metab 1990, 83:1222-1225.
15. Bartalena L, Marcocci C, Tanda M, et al.: Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 1998, 129:632-635.
16. Elliott M, Maini R, Feldmann M, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110.
17. Elliott M, Maini R, Feldmann M, el al.: Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344:1125-1127.
18. McQueen F: The use of biologics in the treatment of rheumatoid arthritis-the good news and the bad news. Aust N Z J Med 1997, 27:175-184.
19. Drevlow B, Lovis R, Haag M, et al.: Recombinant human interleukin-1 receptor type in the treatment of patienta with active rheumatoid arthritis. Arthritis Rheum 1996, 39:257-265.
20. Balazs C, Kiss E, Vamos A, et al.: Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy, J Clin Endocrinol Metab 1997, 82:1999-2002.
21. Tan G, Dutton C, Bahn R: Interleukin-1 receptor antagonist and soluble interleukin-1 receptor inhibit interlcukin-1 glycosaminoglycan production in cultured human orbital fibroblasts from patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 1995, 81:449-452.
22. Prummel M, Wiersinga W: Immunomodulatory treatment of Graves' ophthalmopathy. Thyroid 1996, 8:545-548. This paper reviews the efficacy of the various immunomodulatory therapies for GO, including corticosteroids, radiotherapy, immunoglobutins, cyclosporine, and plasmapheresis.